



Celldex Therapeutics, Inc.
Investor Relations Department
119 Fourth Avenue
Needham, MA 02494-2725
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CLDX ¹

Last Trade:	0.75
Trade Time:	4:00 PM ET Apr 25, 2018
Change:	0.03 (4.810%)
Day Range	0.67 - 0.76
52-Week Range	0.65 - 3.42
Volume	5,823,576
Market Cap. (\$M)	106.826
Shares Out (M)	143.390

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Apr 20, 2018

[Data from Multiple Celldex Programs Presented at American Association for Cancer Research \(AACR\) Annual Meeting 2018](#)

Apr 16, 2018

[Celldex's METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint](#)

Mar 7, 2018

[Celldex Provides Corporate Update and Reports Full Year 2017 Results](#)

Mar 2, 2018

[Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference](#)

Nov 30, 2017

[Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Mar 7, 2018

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Definitive Proxy Statement](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)